Cargando…
P865: BIOMARKER ANALYSIS TO SUPPORT DOSE OPTIMIZATION OF IBERDOMIDE AS MONOTHERAPY AND IN COMBINATION WITH STANDARD OF CARE TREATMENTS FOR MULTIPLE MYELOMA FROM A PHASE 1/2 TRIAL
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430242/ http://dx.doi.org/10.1097/01.HS9.0000846340.95760.ac |
| _version_ | 1784779707289436160 |
|---|---|
| author | Amatangelo, M. Cheng, Y. Pierceall, W. van de Donk, N. W. Lonial, S. Wang, M. Emerson, J. Hong, K. Maciag, P. Peluso, T. Gandhi, A. Thakurta, A. |
| author_facet | Amatangelo, M. Cheng, Y. Pierceall, W. van de Donk, N. W. Lonial, S. Wang, M. Emerson, J. Hong, K. Maciag, P. Peluso, T. Gandhi, A. Thakurta, A. |
| author_sort | Amatangelo, M. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9430242 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94302422022-08-31 P865: BIOMARKER ANALYSIS TO SUPPORT DOSE OPTIMIZATION OF IBERDOMIDE AS MONOTHERAPY AND IN COMBINATION WITH STANDARD OF CARE TREATMENTS FOR MULTIPLE MYELOMA FROM A PHASE 1/2 TRIAL Amatangelo, M. Cheng, Y. Pierceall, W. van de Donk, N. W. Lonial, S. Wang, M. Emerson, J. Hong, K. Maciag, P. Peluso, T. Gandhi, A. Thakurta, A. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9430242/ http://dx.doi.org/10.1097/01.HS9.0000846340.95760.ac Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Amatangelo, M. Cheng, Y. Pierceall, W. van de Donk, N. W. Lonial, S. Wang, M. Emerson, J. Hong, K. Maciag, P. Peluso, T. Gandhi, A. Thakurta, A. P865: BIOMARKER ANALYSIS TO SUPPORT DOSE OPTIMIZATION OF IBERDOMIDE AS MONOTHERAPY AND IN COMBINATION WITH STANDARD OF CARE TREATMENTS FOR MULTIPLE MYELOMA FROM A PHASE 1/2 TRIAL |
| title | P865: BIOMARKER ANALYSIS TO SUPPORT DOSE OPTIMIZATION OF IBERDOMIDE AS MONOTHERAPY AND IN COMBINATION WITH STANDARD OF CARE TREATMENTS FOR MULTIPLE MYELOMA FROM A PHASE 1/2 TRIAL |
| title_full | P865: BIOMARKER ANALYSIS TO SUPPORT DOSE OPTIMIZATION OF IBERDOMIDE AS MONOTHERAPY AND IN COMBINATION WITH STANDARD OF CARE TREATMENTS FOR MULTIPLE MYELOMA FROM A PHASE 1/2 TRIAL |
| title_fullStr | P865: BIOMARKER ANALYSIS TO SUPPORT DOSE OPTIMIZATION OF IBERDOMIDE AS MONOTHERAPY AND IN COMBINATION WITH STANDARD OF CARE TREATMENTS FOR MULTIPLE MYELOMA FROM A PHASE 1/2 TRIAL |
| title_full_unstemmed | P865: BIOMARKER ANALYSIS TO SUPPORT DOSE OPTIMIZATION OF IBERDOMIDE AS MONOTHERAPY AND IN COMBINATION WITH STANDARD OF CARE TREATMENTS FOR MULTIPLE MYELOMA FROM A PHASE 1/2 TRIAL |
| title_short | P865: BIOMARKER ANALYSIS TO SUPPORT DOSE OPTIMIZATION OF IBERDOMIDE AS MONOTHERAPY AND IN COMBINATION WITH STANDARD OF CARE TREATMENTS FOR MULTIPLE MYELOMA FROM A PHASE 1/2 TRIAL |
| title_sort | p865: biomarker analysis to support dose optimization of iberdomide as monotherapy and in combination with standard of care treatments for multiple myeloma from a phase 1/2 trial |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430242/ http://dx.doi.org/10.1097/01.HS9.0000846340.95760.ac |
| work_keys_str_mv | AT amatangelom p865biomarkeranalysistosupportdoseoptimizationofiberdomideasmonotherapyandincombinationwithstandardofcaretreatmentsformultiplemyelomafromaphase12trial AT chengy p865biomarkeranalysistosupportdoseoptimizationofiberdomideasmonotherapyandincombinationwithstandardofcaretreatmentsformultiplemyelomafromaphase12trial AT pierceallw p865biomarkeranalysistosupportdoseoptimizationofiberdomideasmonotherapyandincombinationwithstandardofcaretreatmentsformultiplemyelomafromaphase12trial AT vandedonknw p865biomarkeranalysistosupportdoseoptimizationofiberdomideasmonotherapyandincombinationwithstandardofcaretreatmentsformultiplemyelomafromaphase12trial AT lonials p865biomarkeranalysistosupportdoseoptimizationofiberdomideasmonotherapyandincombinationwithstandardofcaretreatmentsformultiplemyelomafromaphase12trial AT wangm p865biomarkeranalysistosupportdoseoptimizationofiberdomideasmonotherapyandincombinationwithstandardofcaretreatmentsformultiplemyelomafromaphase12trial AT emersonj p865biomarkeranalysistosupportdoseoptimizationofiberdomideasmonotherapyandincombinationwithstandardofcaretreatmentsformultiplemyelomafromaphase12trial AT hongk p865biomarkeranalysistosupportdoseoptimizationofiberdomideasmonotherapyandincombinationwithstandardofcaretreatmentsformultiplemyelomafromaphase12trial AT maciagp p865biomarkeranalysistosupportdoseoptimizationofiberdomideasmonotherapyandincombinationwithstandardofcaretreatmentsformultiplemyelomafromaphase12trial AT pelusot p865biomarkeranalysistosupportdoseoptimizationofiberdomideasmonotherapyandincombinationwithstandardofcaretreatmentsformultiplemyelomafromaphase12trial AT gandhia p865biomarkeranalysistosupportdoseoptimizationofiberdomideasmonotherapyandincombinationwithstandardofcaretreatmentsformultiplemyelomafromaphase12trial AT thakurtaa p865biomarkeranalysistosupportdoseoptimizationofiberdomideasmonotherapyandincombinationwithstandardofcaretreatmentsformultiplemyelomafromaphase12trial |